RETRACTED: Bone marrow mesenchymal stem cells-derived exosomal microRNA-185 represses ventricular remolding of mice with myocardial infarction by inhibiting SOCS2

Li, Yanbing; Zhou, Jie; Zhang, Ou; Wu, Xuejiao; Guan, Xiaoxu; Xue, Yan; Liu, Siyuan; Zhuang, Xianjing; Miao, Guobin; Zhang, Lin

doi:10.1016/j.intimp.2019.106156

Cited by 49 publications

(56 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The normal control (equal amount of PBS), the miR-133a negative control (NC), the miR-133a over-expression (Ad-miR-133a), and miR-133a low-expression (Adas-miR-133a) (Hanbio Biotechnology Co., Ltd., Shanghai, China) were transfected with BMSCs in line with 100 multiplicity of infection (MOI). The BMSCs were cultured, and the corresponding exosomes (NC Exo , NC Exo , Ad-miR-133a Exo , and Adas-miR-133a Exo ) were obtained through ultracentrifugation [ 20 ].…”

Section: Methodsmentioning

confidence: 99%

RETRACTED ARTICLE: Bone Marrow Mesenchymal Stem Cell-Derived Exosomal MicroRNA-133a Restrains Myocardial Fibrosis and Epithelial–Mesenchymal Transition in Viral Myocarditis Rats Through Suppressing MAML1

Jin

Wang

et al. 2021

Nanoscale Res Lett

View full text Add to dashboard Cite

Myocarditis is a disease characterized by localized or diffuse inflammation of the myocardium without efficient treatment. This study explored the regulatory mechanism of microRNA-133 (miR-133) secreted from bone marrow mesenchymal stem cell-derived exosome (BMSC-Exo) on myocardial fibrosis and epithelial–mesenchymal transition (EMT) in viral myocarditis (VMC) rats through regulating mastermind-like 1 (MAML1). BMSCs in rats were isolated and cultured to identify their immune phenotype and osteogenic and adipogenic ability, and BMSC-Exo were extracted and identified. Exosomes were obtained through ultracentrifugation, which were identified by transmission electron microscope and western blot analysis. The rats were injected with Coxsackie B3 virus for preparation of VMC model, and cardiomyocytes were isolated, cultured and grouped in the same way as animal experiments (NCExo, Ad-miR-133aExo, Adas-miR-133aExo). In vivo and in vitro experiments were conducted to figure out the roles of exosomal miR-133a and MAML1 in inflammation, apoptosis, EMT, fibrosis, and cell viability. The targeting relationship between miR-133a and MAML1 was verified by dual luciferase reporter gene assay. BMSC-Exo raised miR-133a expression in VMC rats and effectively improved the VMC rat cardiac function and myocardial fibrosis, increased cardiomyocyte viability and inhibited the EMT process. Elevated miR-133a in exosomes strengthened the improvements. Silenced miR-133a effectively reversed the effects of BMSC-Exo on VMC rats. miR-133a targeted MAML1. Inhibition of MAML1 improved cardiac function and myocardial fibrosis in VMC rats and could reverse the effect of miR-133a-silenced exosomes on VMC rats. Our study suggests that elevated exosomal miR-133a suppresses myocardial fibrosis and EMT in rats with VMC via down-regulating MAML1, thereby inhibiting the progression of myocarditis.

show abstract

Section: Methodsmentioning

confidence: 99%

RETRACTED ARTICLE: Bone Marrow Mesenchymal Stem Cell-Derived Exosomal MicroRNA-133a Restrains Myocardial Fibrosis and Epithelial–Mesenchymal Transition in Viral Myocarditis Rats Through Suppressing MAML1

Jin

Wang

et al. 2021

Nanoscale Res Lett

View full text Add to dashboard Cite

show abstract

“…Overexpression of SOCS2 reversed the regenerative effects of miR-185. miR-185 decelerated the rate of apoptosis in cardiac tissue post-MI with an observed decrease in BAX expression and increase in Bcl-2 expression (118).…”

Section: Cardiac Regenerationmentioning

confidence: 96%

Recent Insight on the Non-coding RNAs in Mesenchymal Stem Cell-Derived Exosomes: Regulatory and Therapeutic Role in Regenerative Medicine and Tissue Engineering

Pant

Juric

Bošnjak

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Advances in the field of regenerative medicine and tissue engineering over the past few decades have paved the path for cell-free therapy. Numerous stem cell types, including mesenchymal stem cells (MSCs), have been reported to impart therapeutic effects via paracrine secretion of exosomes. The underlying factors and the associated mechanisms contributing to these MSC-derived exosomes' protective effects are, however, poorly understood, limiting their application in the clinic. The exosomes exhibit a diversified repertoire of functional non-coding RNAs (ncRNAs) and have the potential to transfer these biologically active transcripts to the recipient cells, where they are found to modulate a diverse array of functions. Altered expression of the ncRNAs in the exosomes has been linked with the regenerative potential and development of various diseases, including cardiac, neurological, skeletal, and cancer. Also, modulating the expression of ncRNAs in these exosomes has been found to improve their therapeutic impact. Moreover, many of these ncRNAs are expressed explicitly in the MSC-derived exosomes, making them ideal candidates for regenerative medicine, including tissue engineering research. In this review, we detail the recent advances in regenerative medicine and summarize the evidence supporting the altered expression of the ncRNA repertoire specific to MSCs under different degenerative diseases. We also discuss the therapeutic role of these ncRNA for the prevention of these various degenerative diseases and their future in translational medicine.

show abstract

“…Moreover, human umbilical cord derived MSC-Exos protected cardiomyocytes from AMI injury by transferring miR-19a, targeting SOX6, activating AKT, and inhibiting JNK3/caspase-3 activation[ 121 ]. Also, bone marrow derived exosomal miR-185 suppressed ventricular remolding, myocardial injury, and cardiomyocyte apoptosis, and improved the cardiac function of MI mice by inhibiting SOCS2[ 122 ].…”

Section: Therapeutic Potential Of Msc-exos In Regenerative Medicinementioning

confidence: 99%

Mesenchymal stem cell-derived exosomes: Toward cell-free therapeutic strategies in regenerative medicine

Yang

et al. 2020

WJSC

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are multipotent stem cells with marked potential for regenerative medicine because of their strong immunosuppressive and regenerative abilities. The therapeutic effects of MSCs are based in part on their secretion of biologically active factors in extracellular vesicles known as exosomes. Exosomes have a diameter of 30-100 nm and mediate intercellular communication and material exchange. MSC-derived exosomes (MSC-Exos) have potential for cell-free therapy for diseases of, for instance, the kidney, liver, heart, nervous system, and musculoskeletal system. Hence, MSC-Exos are an alternative to MSC-based therapy for regenerative medicine. We review MSC-Exos and their therapeutic potential for a variety of diseases and injuries.

show abstract

RETRACTED: Bone marrow mesenchymal stem cells-derived exosomal microRNA-185 represses ventricular remolding of mice with myocardial infarction by inhibiting SOCS2

Cited by 49 publications

References 28 publications

RETRACTED ARTICLE: Bone Marrow Mesenchymal Stem Cell-Derived Exosomal MicroRNA-133a Restrains Myocardial Fibrosis and Epithelial–Mesenchymal Transition in Viral Myocarditis Rats Through Suppressing MAML1

RETRACTED ARTICLE: Bone Marrow Mesenchymal Stem Cell-Derived Exosomal MicroRNA-133a Restrains Myocardial Fibrosis and Epithelial–Mesenchymal Transition in Viral Myocarditis Rats Through Suppressing MAML1

Recent Insight on the Non-coding RNAs in Mesenchymal Stem Cell-Derived Exosomes: Regulatory and Therapeutic Role in Regenerative Medicine and Tissue Engineering

Mesenchymal stem cell-derived exosomes: Toward cell-free therapeutic strategies in regenerative medicine

Contact Info

Product

Resources

About